Development of an NPM1 mutation in CMML qualifies it as acute myeloid leukaemia (AML) regardless of the blast count, according to the WHO-HAEM5, whereas the ICC requires ≥ 10% blasts. This evidence concerns the gene NPM1 and chronic myelomonocytic leukemia.